(2008). AA: Advances in targeting the Ras/Raf/MEK/Erk mitogenactivated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res
Association: World Medical Association Declaration of Helsinki: Ethical Principales for Medical Research involving Human Subjects.[http://www.wma.net/en/30publications/10policies/b3/17c.pdf].
(2010). CA: Stimulus-induced uncoupling of extracellular signal-regulated kinase phosphorylation from nuclear localization is dependent on docking domain interactions.
(1999). de Velde CJ: Cancer surgery: the last 25 years. Cancer Treat Rev
(1995). Decreased MAP kinase activity in human gastric adenocarcinoma.
(2011). Forman D: Global cancer statistics.
(2002). Global cancer statistics
(1995). HM: A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer
(2010). Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Med Oncol
(2011). Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology
(2003). JG: Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet
(2007). Kolch W: MAP kinase signalling pathways in cancer. Oncogene
(2000). Kolch W: Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol
(2008). Kolch W: Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability.
(2005). Kolch W: Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res
(1999). Kolch W: Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature
(2009). Lopes JM: Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch
(2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ ERK pathway by protein interactions.
(2008). MR: Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets
(2003). Prospective cohort study of comprehensive prevention to gastric cancer.
(2006). Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients.
(2008). Resnick MB: Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res
(1995). RJ: Gastric carcinoma.
(2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta
(2005). Rosner MR: Modulation of the MAP kinase signaling cascade by Raf kinase inhibitory protein. Cell Res
(2010). Solit DB: Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res
(2008). Sugihara K: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res
(2009). Sugihara K: Relation between outcomes and localisation of pmTOR expression in gastric cancer.
(2008). Tan D: Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NFkappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci
(2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer
(2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene
(2004). The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol
(2010). ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet
(1998). Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues.
(1999). Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer.
(1987). Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature